Table 3.

Sites of metastasis.

		Driver alteration, n(%)			P-value
Metastatic Site	All (N=333)	ALK+ (N=119)	EGFR+ (N=116)	EGFR-/ALK- (N=98)	ALK+ vs. EGFR+	ALK+ vs/ EGFR-/ALK-
Thoracic Node
No	32 (10%)	8 (7%)	20 (17%)	4 (4%)	0.02	0.55
Yes	301 (90%)	111 (93%)	96 (83%)	94 (96%)
Intrathoracic
No	76 (23%)	34 (29%)	28 (24%)	14 (14%)	0.46	0.01
Yes	257 (77%)	85 (71%)	88 (76%)	84 (86%)
Lung
No	166 (50%)	96 (81%)	39 (34%)	31 (32%)	<0.01	<0.01
Yes	167 (50%)	23 (19%)	77 (66%)	67 (68%)
Pleural mets
No	192 (58%)	64 (54%)	85 (73%)	43 (44%)	<0.01	0.17
Yes	141 (42%)	55 (46%)	31 (27%)	55 (56%)
Lymphangitic carcinomatosis
No	263 (79%)	75 (63%)	102 (88%)	86 (88%)	<0.01	<0.01
Yes	70 (21%)	44 (37%)	14 (12%)	12 (12%)
Pericardium
No	329 (99%)	116 (97%)	116 (100%)	97 (99%)	0.25	0.63
Yes	4 (1%)	3 (3%)	0 (0%)	1 (1%)
Extra-thoracic
No	95 (29%)	33 (28%)	32 (28%)	30 (31%)	>0.99	0.66
Yes	238 (71%)	86 (72%)	84 (72%)	68 (69%)
Intra-abdominal
No	233 (70%)	87 (73%)	81 (70%)	65 (66%)	0.66	0.30
Yes	100 (30%)	32 (27%)	35 (30%)	33 (34%)
Adrenal
No	278 (83%)	111 (93%)	100 (86%)	67 (68%)	0.09	<0.01
Yes	55 (17%)	8 (7%)	16 (14%)	31 (32%)
Liver
No	277 (83%)	93 (78%)	92 (79%)	92 (94%)	0.87	<0.01
Yes	56 (17%)	26 (22%)	24 (21%)	6 (6%)
Spleen
No	328 (98%)	114 (96%)	116 (100%)	98 (100%)	0.06	0.07
Yes	5 (2%)	5 (4%)	0 (0%)	0 (0%)
Bone
No	195 (59%)	65 (55%)	67 (58%)	63 (64%)	0.69	0.17
Yes	138 (41%)	54 (45%)	49 (42%)	35 (36%)
Bone type
None	198 (59%)	65 (55%)	68 (59%)	65 (66%)	<0.01	<0.01
Lytic	93 (28%)	26 (22%)	40 (34%)	27 (28%)
Sclerotic	42 (13%)	28 (24%)	8 (7%)	6 (6%)
Brain
No	227 (68%)	90 (76%)	69 (59%)	68 (69%)	0.01	0.36
Yes	106 (32%)	29 (24%)	47 (41%)	30 (31%)
Distant lymph node
No	298 (89%)	95 (80%)	114 (98%)	89 (91%)	<0.01	0.04
Yes	35 (11%)	24 (20%)	2 (2%)	9 (9%)
Soft tissue
No	316 (95%)	112 (94%)	116 (100%)	88 (90%)	0.01	0.31
Yes	17 (5%)	7 (6%)	0 (0%)	10 (10%)